Fragaki Konstantina, Chaussenot Annabelle, Benoist Jean-François, Ait-El-Mkadem Samira, Bannwarth Sylvie, Rouzier Cécile, Cochaud Charlotte, Paquis-Flucklinger Véronique
School of Medicine, IRCAN, UMR CNRS 7284/INSERM U1081/UNS, Nice Sophia-Antipolis University, 28 av de Valombrose, 06107, Nice Cedex 2, France.
Department of Medical Genetics, Nice Teaching Hospital, National Centre for Mitochondrial Diseases, Nice, France.
Biol Res. 2016 Jan 8;49:4. doi: 10.1186/s40659-015-0065-0.
Coenzyme Q10 (CoQ10 or ubiquinone) deficiency can be due either to mutations in genes involved in CoQ10 biosynthesis pathway, or to mutations in genes unrelated to CoQ10 biosynthesis. CoQ10 defect is the only oxidative phosphorylation disorder that can be clinically improved after oral CoQ10 supplementation. Thus, early diagnosis, first evoked by mitochondrial respiratory chain (MRC) spectrophotometric analysis, then confirmed by direct measurement of CoQ10 levels, is of critical importance to prevent irreversible damage in organs such as the kidney and the central nervous system. It is widely reported that CoQ10 deficient patients present decreased quinone-dependent activities (segments I + III or G3P + III and II + III) while MRC activities of complexes I, II, III, IV and V are normal. We previously suggested that CoQ10 defect may be associated with a deficiency of CoQ10-independent MRC complexes. The aim of this study was to verify this hypothesis in order to improve the diagnosis of this disease.
To determine whether CoQ10 defect could be associated with MRC deficiency, we quantified CoQ10 by LC-MSMS in a cohort of 18 patients presenting CoQ10-dependent deficiency associated with MRC defect. We found decreased levels of CoQ10 in eight patients out of 18 (45 %), thus confirming CoQ10 disease.
Our study shows that CoQ10 defect can be associated with MRC deficiency. This could be of major importance in clinical practice for the diagnosis of a disease that can be improved by CoQ10 supplementation.
辅酶Q10(CoQ10或泛醌)缺乏症可能是由于参与CoQ10生物合成途径的基因突变,也可能是由于与CoQ10生物合成无关的基因突变。CoQ10缺陷是唯一一种口服CoQ10补充后临床症状可改善的氧化磷酸化障碍疾病。因此,早期诊断(首先通过线粒体呼吸链(MRC)分光光度分析引发,然后通过直接测量CoQ10水平进行确认)对于预防肾脏和中枢神经系统等器官的不可逆损伤至关重要。广泛报道称,CoQ10缺乏症患者的醌依赖性活性(片段I + III或G3P + III以及II + III)降低,而复合物I、II、III、IV和V的MRC活性正常。我们之前曾提出CoQ10缺陷可能与不依赖CoQ10的MRC复合物缺乏有关。本研究的目的是验证这一假设,以改善该疾病的诊断。
为了确定CoQ10缺陷是否与MRC缺乏有关,我们通过液相色谱-串联质谱法(LC-MSMS)对18例表现出与MRC缺陷相关的CoQ10依赖性缺乏的患者进行了CoQ10定量分析。我们发现18例患者中有8例(45%)CoQ10水平降低,从而证实了CoQ10疾病。
我们的研究表明,CoQ10缺陷可能与MRC缺乏有关。这对于临床实践中诊断一种可通过补充CoQ10改善的疾病可能具有重要意义。